1.Sales and profit
See section →- Chemomab Therapeutics Ltd. lost $9.0M in fiscal 2025. From fiscal 2018 to 2025, diluted EPS grew −44.4% a year.
Chemomab Therapeutics Ltd.
CMMB Nasdaq Pharmaceutical Preparations Financials FY2018–FY2025
- Today
- 6.4%
- Previous close
- $1.09
- Market cap
- —
- P/E
- —
- Day range
-
$1.01 $1.16
- 52-week range
-
$1.00 $3.06
Last close · Oct 30, 2026
$1.16
−$1.82 (−61.07%) past year
KIRA’s summary AI analyst
Hi! I read Chemomab Therapeutics Ltd.’s latest annual report (fiscal 2025). Here is what stands out:
2 to watch
2.Cash and shareholders
See section →- Free cash flow was −$11.1M in fiscal 2025. At that burn of $11.1M a year, its $7.6M of cash and short-term investments would last about 0.7 years.
- In the last 12 months, insiders bought $0.0M and sold $0.0M of shares on the open market.
Chemomab Therapeutics Ltd. in 30 seconds
Good So-so Weak
Weak
Does it make a profit?
−$9.0M
No. It lost money last year.
Weak
How long would its cash last?
0.7 yrs
Not long. It burns $11.1M a year and holds $7.6M, under a year at that pace, so it may need new money soon.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
—
Oct 30 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Revenue and margins
Revenue
FY18
Revenue —
FY19
Revenue —
FY20
Revenue —
FY21
Revenue —
FY22
Revenue —
FY23
Revenue —
FY24
Revenue —
FY25
Revenue —
Margins, % of revenue
FY18
Gross —
Operating —
Net —
FCF —
FY19
Gross —
Operating —
Net —
FCF —
FY20
Gross —
Operating —
Net —
FCF —
FY21
Gross —
Operating —
Net —
FCF —
FY22
Gross —
Operating —
Net —
FCF —
FY23
Gross —
Operating —
Net —
FCF —
FY24
Gross —
Operating —
Net —
FCF —
FY25
Gross —
Operating —
Net —
FCF —
Gross
Operating
Net
FCF
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Net income and earnings per share
Loss periods are shown in red.
KIRA summarises the numbers
-
Chemomab Therapeutics Ltd. lost $9.0M in fiscal 2025.
From fiscal 2018 to 2025, diluted EPS grew −44.4% a year.
Net income
FY18
Net income −$13.8M
FY19
Net income −$27.1M
FY20
Net income −$6.0M
FY21
Net income −$12.5M
FY22
Net income −$27.6M
FY23
Net income −$24.2M
FY24
Net income −$13.9M
FY25
Net income −$9.0M
Net income
Q3 '21
Net income −$3.0M
Q4 '21
Net income −$5.0M
Q1 '22
Net income −$5.1M
Q2 '22
Net income −$6.2M
Q3 '22
Net income −$8.1M
Q4 '22
Net income −$8.3M
Q1 '23
Net income −$8.8M
Q2 '23
Net income −$8.0M
Q1 '24
Net income −$3.9M
Q2 '24
Net income −$3.6M
Q1 '25
Net income −$3.3M
Q2 '25
Net income −$2.1M
Diluted EPS
FY18
Diluted EPS $1.09
FY19
Diluted EPS $0.79
FY20
Diluted EPS $0.04
FY21
Diluted EPS $0.06
FY22
Diluted EPS $0.12
FY23
Diluted EPS $0.10
FY24
Diluted EPS $0.04
FY25
Diluted EPS $0.02
Diluted EPS
Q3 '21
Diluted EPS $0.01
Q4 '21
Diluted EPS $0.02
Q1 '22
Diluted EPS $0.02
Q2 '22
Diluted EPS $0.03
Q3 '22
Diluted EPS $0.04
Q4 '22
Diluted EPS $0.04
Q1 '23
Diluted EPS $0.04
Q2 '23
Diluted EPS $0.04
Q1 '24
Diluted EPS —
Q2 '24
Diluted EPS $0.01
Q1 '25
Diluted EPS —
Q2 '25
Diluted EPS —
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
Cash from operations minus capital spending.
KIRA summarises the numbers
-
Free cash flow was −$11.1M in fiscal 2025.
At that burn of $11.1M a year, its $7.6M of cash and short-term investments would last about 0.7 years.
Free cash flow
FY18
Free cash flow −$14.4M
FY19
Free cash flow −$16.6M
FY20
Free cash flow −$5.3M
FY21
Free cash flow −$12.6M
FY22
Free cash flow −$20.4M
FY23
Free cash flow −$23.6M
FY24
Free cash flow −$15.4M
FY25
Free cash flow −$11.1M
Free cash flow
Q3 '21
Free cash flow −$2.6M
Q4 '21
Free cash flow −$3.0M
Q1 '22
Free cash flow −$3.7M
Q2 '22
Free cash flow −$5.7M
Q3 '22
Free cash flow −$5.3M
Q4 '22
Free cash flow −$5.7M
Q1 '23
Free cash flow −$7.2M
Q2 '23
Free cash flow −$7.5M
Q1 '24
Free cash flow —
Q2 '24
Free cash flow —
Q1 '25
Free cash flow —
Q2 '25
Free cash flow —
Cash from operations vs capital spending
FY18
Cash from operations −$14.2M
Capital spending $0.2M
FY19
Cash from operations −$16.5M
Capital spending $0.1M
FY20
Cash from operations −$5.2M
Capital spending $0.0M
FY21
Cash from operations −$12.4M
Capital spending $0.2M
FY22
Cash from operations −$20.4M
Capital spending $0.1M
FY23
Cash from operations −$23.6M
Capital spending $0.0M
FY24
Cash from operations −$15.4M
Capital spending $0.0M
FY25
Cash from operations −$11.1M
Capital spending $0.0M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '21
Cash from operations −$2.6M
Capital spending $0.0M
Q4 '21
Cash from operations −$2.9M
Capital spending $0.1M
Q1 '22
Cash from operations −$3.7M
Capital spending $0.0M
Q2 '22
Cash from operations −$5.7M
Capital spending $0.0M
Q3 '22
Cash from operations −$5.3M
Capital spending $0.0M
Q4 '22
Cash from operations −$5.7M
Capital spending $0.0M
Q1 '23
Cash from operations −$7.2M
Capital spending $0.0M
Q2 '23
Cash from operations −$7.5M
Capital spending $0.0M
Q1 '24
Cash from operations —
Capital spending —
Q2 '24
Cash from operations —
Capital spending —
Q1 '25
Cash from operations —
Capital spending —
Q2 '25
Cash from operations —
Capital spending —
Cash from operations
Capital spending
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Dividends, buybacks and share count
Dividends and buybacks
FY18
Dividends —
Buybacks —
FY19
Dividends —
Buybacks —
FY20
Dividends —
Buybacks —
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY23
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
Diluted shares outstanding (annual)
FY18
Diluted shares 0.01B
FY19
Diluted shares 0.00B
FY20
Diluted shares 0.14B
FY21
Diluted shares 0.21B
FY22
Diluted shares 0.23B
FY23
Diluted shares 0.23B
FY24
Diluted shares 0.36B
FY25
Diluted shares 0.51B
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
KIRA summarises the numbers
-
In the last 12 months, insiders bought $0.0M and sold $0.0M of shares on the open market.
Bought, 12 months
$0.0M
1 insider
Sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 28, 2026 | Neil Harris CohenDirector | Sold | 1,000 | $2.80 | $0.0M | Form 4 |
| Aug 27, 2026 | Neil Harris CohenDirector | Sold | 1,304 | $2.85 | $0.0M | Form 4 |
| May 29, 2026 | George Adi MorChief Executive Officer, Director | Bought | 9,804 | $2.07 | $0.0M | Form 4 |
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Chemomab Therapeutics Ltd. can carry it.
Cash vs debt (incl. leases)
FY18
Cash $7.5M
Debt —
FY19
Cash $17.6M
Debt —
FY20
Cash $11.7M
Debt —
FY21
Cash $15.2M
Debt —
FY22
Cash $13.5M
Debt —
FY23
Cash $9.3M
Debt —
FY24
Cash $6.1M
Debt —
FY25
Cash $7.6M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $15.2M | $13.5M | $9.3M | $6.1M | $7.6M |
| Current ratio | 23.7x | 6.2x | 4.3x | 5.0x | 9.1x |
| Quick ratio | 23.7x | 6.2x | 4.3x | 5.0x | 9.1x |
| Total assets | $64.4M | $43.1M | $22.2M | $17.0M | $13.8M |
| Total liabilities | $2.9M | $6.8M | $5.2M | $3.4M | $1.5M |
| Shareholders' equity | $61.5M | $36.2M | $17.0M | $13.5M | $12.3M |
| Net debt (− = net cash) | — | — | — | — | — |
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Return on capital, equity and assets (annual)
FY18
Return on capital —
Return on equity −140.7%
Return on assets −108.1%
FY19
Return on capital —
Return on equity −244.6%
Return on assets −166.8%
FY20
Return on capital —
Return on equity −51.4%
Return on assets −36.9%
FY21
Return on capital —
Return on equity −34.5%
Return on assets −32.5%
FY22
Return on capital —
Return on equity −56.6%
Return on assets −51.5%
FY23
Return on capital —
Return on equity −91.0%
Return on assets −74.3%
FY24
Return on capital —
Return on equity −91.3%
Return on assets −71.3%
FY25
Return on capital —
Return on equity −69.5%
Return on assets −58.5%
Return on capital
Return on equity
Return on assets
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| F-score | — / 6 | — / 6 | — / 6 | — / 6 | — / 6 |
| Accruals ratio | −0.3% | −13.5% | −1.9% | 7.4% | 13.9% |
| Altman Z'' | — | — | — | −51.42 | −66.40 |
| Net income is positive | ✕ | ✕ | ✕ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ | ✕ | ✕ |
| Return on assets rose | ✓ | ✕ | ✕ | ✓ | ✓ |
| Cash from operations exceeds net income | ✓ | ✓ | ✓ | ✕ | ✕ |
| Debt fell relative to assets | — | — | — | — | — |
| Current ratio rose | ✓ | ✕ | ✕ | ✓ | ✓ |
| Share count didn't rise | ✕ | ✕ | ✕ | ✕ | ✕ |
| Gross margin rose | — | — | — | — | — |
| Revenue rose relative to assets | — | — | — | — | — |
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
All figures
Every number, year by year.
8 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
See the figures for 8 years Hide the figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Research and development | $7.5M | $13.3M | $4.7M | $6.3M | $17.0M | $18.4M | $11.3M | $5.8M |
| Operating income | — | — | — | — | — | — | −$103M | −$112M |
| Pretax income | $13.5M | $27.1M | $6.0M | −$12.5M | −$28.2M | −$24.2M | −$13.9M | −$9.0M |
| Income tax | $0.3M | $0.0M | $0.0M | $0.0M | −$0.5M | $0.0M | $0.0M | $0.0M |
| Net income | −$13.8M | −$27.1M | −$6.0M | −$12.5M | −$27.6M | −$24.2M | −$13.9M | −$9.0M |
| Diluted EPS | $1.09 | $0.79 | $0.04 | $0.06 | $0.12 | $0.10 | $0.04 | $0.02 |
| Diluted shares | 0.01B | 0.00B | 0.14B | 0.21B | 0.23B | 0.23B | 0.36B | 0.51B |
| Cash flow | ||||||||
| Cash from operations | −$14.2M | −$16.5M | −$5.2M | −$12.4M | −$20.4M | −$23.6M | −$15.4M | −$11.1M |
| Capital expenditure | $0.2M | $0.1M | $0.0M | $0.2M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | −$14.4M | −$16.6M | −$5.3M | −$12.6M | −$20.4M | −$23.6M | −$15.4M | −$11.1M |
| Depreciation and amortization | $0.1M | $0.3M | $0.0M | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M |
| Stock-based compensation | $1.9M | $1.2M | $0.1M | $2.0M | $3.2M | $1.5M | $0.6M | $0.6M |
| Balance sheet | ||||||||
| Cash and short-term investments | $7.5M | $17.6M | $11.7M | $15.2M | $13.5M | $9.3M | $6.1M | $7.6M |
| Current assets | $10.9M | $18.2M | $11.8M | $62.7M | $41.7M | $20.9M | $16.0M | $13.4M |
| Current liabilities | $2.7M | $4.1M | $1.3M | $2.7M | $6.7M | $4.8M | $3.2M | $1.5M |
| Property and equipment, net | $0.4M | $0.2M | $0.2M | $0.4M | $0.4M | $0.3M | $0.3M | $0.2M |
| Total assets | $12.8M | $19.8M | $12.5M | $64.4M | $43.1M | $22.2M | $17.0M | $13.8M |
| Total liabilities | $3.0M | $4.8M | $1.7M | $2.9M | $6.8M | $5.2M | $3.4M | $1.5M |
| Shareholders' equity | $9.8M | $12.4M | $10.8M | $61.5M | $36.2M | $17.0M | $13.5M | $12.3M |
| Returns | ||||||||
| Return on capital employed | — | — | — | — | — | — | −749.3% | −908.1% |
| Return on equity | −140.7% | −244.6% | −51.4% | −34.5% | −56.6% | −91.0% | −91.3% | −69.5% |
| Return on assets | −108.1% | −166.8% | −36.9% | −32.5% | −51.5% | −74.3% | −71.3% | −58.5% |
| Return on tangible equity | −140.7% | −219.2% | −55.1% | −20.3% | −76.3% | −142.5% | −103.0% | −72.9% |
| Growth | ||||||||
| EPS growth | — | −27.5% | −94.4% | 36.4% | 101.7% | −14.9% | −62.1% | −53.8% |
| Share count change | — | −99.7% | 397,445.1% | 51.7% | 9.7% | 3.3% | 52.8% | 42.1% |
| Financial health | ||||||||
| Current ratio | 4.0x | 4.4x | 9.0x | 23.7x | 6.2x | 4.3x | 5.0x | 9.1x |
| Quick ratio | 4.0x | 4.4x | 9.0x | 23.7x | 6.2x | 4.3x | 5.0x | 9.1x |
| Quality scores | ||||||||
| Altman Z'' | — | — | — | — | — | — | −51.4 | −66.4 |
| Accruals ratio | 3.3% | −65.6% | −4.4% | −0.3% | −13.5% | −1.9% | 7.4% | 13.9% |
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
Latest SEC filings
The original documents every number on this page comes from.
Source: SEC EDGAR XBRL filings (CIK 0001534248). Data updated November 1, 2026. Quarterly fourth quarters are the full year minus the first nine months. The ADS ratio could not be read from the filing, so market cap and valuation are not shown. For information only — not investment advice. Check the original filings before relying on any figure.